13F Holdings
中文EN

LPCN Lipocine Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1535955 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-13.4%
TTM net income YoY-70.4%
TTM EPS YoY-22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-269.1%
Net margin-249.2%
FCF margin—
EBITDA margin-267.5%

Returns

ROE-52.9%
ROA-47.5%
ROIC (approx.)-55.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio11.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio3.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.98M$11.20M-$2.85M$500,000$16.14M
R&D expense$8.58M$7.35M$10.18M$8.56M$7.67M
SG&A expense$3.76M$5.00M$4.90M$4.06M$5.33M
Operating income-$10.37M-$1.16M-$17.93M-$12.12M$3.15M
Interest expense———$27,098$203,292
Pretax income-$9.63M$9,033-$16.35M-$10.76M-$634,199
Income tax$200$681$755$681$200
Net income-$9.63M$8,352-$16.35M-$10.76M-$634,399
EBITDA-$10.31M-$1.11M-$17.90M-$12.11M$3.15M
EPS (basic)-1.77—-3.10-2.06-0.01
EPS (diluted)-1.69—-3.14-2.15-0.01
Weighted avg. shares (diluted)5.71M5.42M5.27M5.26M87.62M
Balance sheet
Cash & equivalents$5.21M$6.21M$4.77M$3.15M$2.95M
Short-term investments$9.72M$15.43M$17.26M$29.38M$41.67M
Current assets$16.88M$22.32M$22.86M$34.14M$46.38M
PP&E, net$104,293$165,075$116,095$131,589$7,211
Total assets$17.01M$22.51M$23.00M$37.54M$52.48M
Current liabilities$2.53M$1.51M$2.63M$1.68M$5.62M
Short-term debt————$2.31M
Long-term debt————$1.67M
Total debt————$3.98M
Total liabilities$2.53M$1.51M$2.63M$1.91M$6.91M
Shareholders' equity$14.48M$21.00M$20.37M$35.63M$45.57M
Net debt————$1.03M
Shares outstanding6.16M5.35M5.32M5.23M88.29M
Cash flow statement
Operating cash flow-$9.76M-$1.22M-$11.87M-$11.97M-$4.41M
Capital expenditure—$90,086$13,167$133,831$7,591
Free cash flow—-$1.31M-$11.88M-$12.10M-$4.42M
Investing cash flow$5.89M$2.45M$13.08M$14.29M-$43.78M
Financing cash flow$2.87M$209,340$404,567-$2.13M$26.92M
Depreciation & amortization$60,782$41,106$28,661$9,453$380
Stock-based compensation$242,497$408,551$654,438$636,140$603,946

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.